SciSparc starts a new Phase 2 trial with SCI-110 in AD


On 6 January, SciSparc Ltd., a clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced the recruitment of the first participant in a new Phase IIa clinical trial in Alzheimer's disease (AD). Conducted at the Israeli Alzheimer's Medical Center in Israel, the clinical trial is evaluating the safety, tolerability and efficacy of SCI-110 in people with AD and agitation.

The primary objective of the study is the safety of SCI-110 and the secondary objective is the ability of the drug candidate to ameliorate agitation and other behavioural disturbances in people with AD. The drug candidate SCI-110 contains Dronabinol and the endocannabinoid palmitoylethanolamide, and is designed to stimulate cannabinoid receptors across the Central Nervous System.